Oct 26, 2007 by Brian LawlerAnother Prospect for FlamelIts good week continues with favorable news about a treatment for hepatitis C.
Oct 25, 2007 by Brian LawlerFlamel Gets Upbeat News About CoregFlamel might be earning more than had been calculated from its lead drug, but the company still isn't profitable.
Oct 25, 2007 by Brian LawlerTysabri, Elan, and a PrayerSales of the multiple sclerosis drug are picking up, but probably can't grow into the stock's valuation.
Oct 24, 2007 by Brian LawlerBiogen's Brisk BusinessBiogen releases its third-quarter financial results.
Oct 24, 2007 by Brian LawlerPharmasset on the Fast TrackThe FDA decision is not fantastic news, but it could help.
Oct 22, 2007 by Brian LawlerModest Numbers From Eli LillyIts sales were up for the quarter, but a new drug might be the best indicator of its prospects.
Oct 22, 2007 by Brian LawlerNo Catastrophes at NovartisNovartis stays on track with its third-quarter results.
Oct 22, 2007 by Brian LawlerGilead's on a Drug-Induced HighThe large-cap drugmaker keeps giving investors reason to cheer.
Oct 19, 2007 by Brian LawlerSchering's Gain Is Only a Mild Headache for VertexSchering-Plough's positive study results send shares of Vertex down.
Oct 18, 2007 by Brian LawlerMGI's Quiet GainsThe specialty pharma notches a healthy Q3 and should keep performing well into the future.
Oct 18, 2007 by Brian LawlerGenzyme Shows Off a Drug CandidateA top compound in development could become an important MS treatment.
Oct 17, 2007 by Brian LawlerSmall Dent in the Exelixis ArmorOne of its drugs fails in a phase 2 trial.
Oct 17, 2007 by Brian LawlerFlamel's Frail, Fluctuating FutureThe company's near-term success rides on one Glaxo study.
Oct 16, 2007 by Brian LawlerGenentech Fitting BetterCancer treatment Avastin continues to surge for the company with a jump on the competition.
Oct 16, 2007 by Brian LawlerQuestions Surround a Biogen DealRumors swirl around Biogen after it publicly announces that it's for sale.
Oct 15, 2007 by Brian LawlerSave Your Cash, PfizerA multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems.
Oct 15, 2007 by Brian LawlerA Surprising Decision for TelikIt still doesn't look like its lead drug is helping anyone get better.
